SARS-CoV-2 (COVID-19) Severe Pneumonia (DBCOND0129699)

Identifiers

Synonyms

2019-nCoV Severe Pneumonia / Severe COVID-19 Pneumonia / COVID-19 Severe Pneumonia / Severe COVID 19 Pneumonia / Severe 2019-nCoV Pneumonia / Severe SARS-CoV2 Pneumonia

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04263402	The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia	Methylprednisolone	treatment	4	unknown_status
NCT04333420	Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia	Vilobelimab	treatment	2 / 3	completed
NCT04808882	ANTIcoagulation in Severe COVID-19 Patients	Tinzaparin	treatment	2	completed
NCT04880694	A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019（COVID-19）Pneumonia	STC3141	treatment	2	completed
NCT04412668	Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19	Efzofitimod	treatment	2	completed
NCT04369469	Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia	Ravulizumab	treatment	3	terminated
NCT04435223	Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen	No drug interventions	Not Available	Not Available	completed
NCT04924829	Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19	Tocilizumab	Not Available	Not Available	unknown_status
NCT04376840	Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19	No drug interventions	diagnostic	Not Available	unknown_status